This market reached a value of over $1.7 billion in 2005 and will grow consistently over the next five years.
The US market for orthopedic biomaterials is comprised of Bone graft substitutes (BGS), Spinal machined bone, Osteoarticular allografts, Hyaluronic acid (HA) viscosupplementation, Emerging growth factor (GF) technologies, Platelet concentration systems (PCS) and Autologous chondrocyte implantation (ACI).
